The role of autologous hematopoietic stem cell transplantation in hematologic malignancy
| Autor: | George W. Santos |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lymphoma business.industry medicine.medical_treatment Hematopoietic Stem Cell Transplantation Hematopoietic stem cell Disease Relapse rate Hematopoietic stem cell transplantation Precursor Cell Lymphoblastic Leukemia-Lymphoma Malignancy medicine.disease Transplantation Autologous medicine.anatomical_structure Older patients Internal medicine medicine Hematologic malignancy Humans Multiple Myeloma business |
| Zdroj: | Current Opinion in Oncology. 6:115-121 |
| ISSN: | 1040-8746 |
| DOI: | 10.1097/00001622-199403000-00001 |
| Popis: | Supraintensive cytoreductive therapy with hematopoietic stem cell rescue (HSCR) is able to provide curative therapy in a number of hematologic malignancies. Allogeneic HSCR is limited to less than 50% of patients because of the absence of related or unrelated compatible donors. Autologous HSCR is a viable alternative to allogeneic HSCR and is applicable to a greater number of patients. In addition, because of the absence of graft-versus-host disease, it is applicable to older patients. Although the relapse of malignancy is higher following autologous compared with allogeneic marrow, the disease-free survival for autologous HSCR is often equal to or greater than that seen following allogeneic HSCR. A number of posttransplantation immunological based therapies have shown promise for further decreasing the relapse rate following autologous HSCR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|